Demo Data from EDBT 2026 / reviewers in the wild / expert
Mark G. Bures
dblp:02/3863
· DBLP profile ↗
1ranked-venue papers
0as first author
0since 2021 · last 2000
—ORCID · none
Domains — the database's venue-derived domains; a paper can count in several
Applied, interdisciplinary, general and emerging computing · 1
Expertise — from the expertise taxonomy: the topics of the expert's papers under the CCF categories. A weight counts papers with recency: 1 for a paper about the topic, 0.3 when the topic is its context, halved every five years.
| Interdisciplinary, comprehensive, and emerging computing
1 paper |
Bioinformatics and computational biology · 100% |
Topics — the 3 heaviest of 4, each with the papers that count most for it
| Topic | Weight | Papers | Last | Evidence papers |
|---|---|---|---|---|
Bioinformatics and computational biology › molecular informatics
cheminformatics |
0.0 | 1 | 2000 | Molecular diversity: strategies and concerns (abstract only) · RECOMB 2000 |
Bioinformatics and computational biology › molecular informatics › cheminformatics
molecular diversity |
0.0 | 1 | 2000 | Molecular diversity: strategies and concerns (abstract only) · RECOMB 2000 |
Bioinformatics and computational biology › molecular informatics › cheminformatics
molecular similarity |
0.0 | 1 | 2000 | Molecular diversity: strategies and concerns (abstract only) · RECOMB 2000 |
Methods — techniques the papers use, named apart from their topics
similarity calculation · 0.0molecular descriptors · 0.0
| Year | Publication | Venue | Position |
|---|---|---|---|
| 2000 | Molecular diversity: strategies and concerns (abstract only)abstractAutomation has produced the opportunity to test hundreds of thousands of compounds in a biological test. The challenge of the computational chemist is to select, from the 10180 possible drug-like molecules, those that are most attractive for screening, those that could form the basis of a medicinal chemistry program. Early work focused on selecting diverse compounds, leading to the question of how similar compounds must be in order for them to have similar biological activity. The issue, of course, is how to quantitate the similarity—which molecular descriptors and which similarity calculation provide the best result. More recent work has emphasized the consideration of physical properties to eliminate compounds, with the challenge of finding accurate and comprehensive methods to calculate these properties. Yvonne C. Martin, Mark G. Bures |
RECOMB | 2 |